Aromatase Inhibitors (AIs) are an important component of endocrine therapy in hormone receptor positive low-grade serous ovarian carcinoma and recurrent, metastatic, or high-risk uterine cancers. The risk of osteoporosis or fracture at 2 years on AI therapy ranges up to 15%.NCCN Task Force on bone health in cancer care has specific guidelines on recommended counseling and monitoring for patients on AI therapy.Despite these recommendations, compliance to bone health guidelines within the oncological community is questionable. A quality improvement (QI) project was designed to educate providers on current guidelines. The aim of this QI project was to assess provider compliance with the NCCN recommendations for AI therapy in the gynecologic oncology clinics, as well as patient-related outcomes before and after implementation of the QI initiative.